نتائج البحث 531-540 من 12620 لعملية البحث عن Low testosterone
... T cells to recognize B cell specific tumor markers; however, attempts to treat solid tumors with CAR T ... low risk germ cell tumors after their tumor is removed.
... T-cell (CAR-T) therapy. The most common adverse event after CAR-T therapy is lower than normal blood cells (cytopenia) and up to one third of patients ...
Venetoclax is FDA approved for the treatment of CLL and SLL. The drug combination of acalabrutinib, durvalumab, and venetoclax is experimental and isn't ...
The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill ...
Advanced prostate cancer patient guide. Urology Care Foundation. https://www.urologyhealth.org/educational-resources/advanced-prostate-cancer. Jan.
... low-grade glioma (LGG) not associated with BRAFV600E mutations or systemic neurofibromatosis type 1 (NF1). Cerebrospinal Fluid Biomarkers For Brain Tumors.
Prostate cancer treatment (PDQ) — Patient version. National Cancer Institute. https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq. Accessed ...
Hyperplastic polyps are common but they have a low malignancy potential (3). There is evidence that colonic inflammation plays a major role in colon polyp and ...
The hypothesis is that the early surgery group will have a significantly lower all-cause mortality and incidence of acute aortic events at 2 years of follow up ...
A Study To Evaluate Regional Radiotherapy In Biomarker Low-Risk Node Positive Breast Cancer ... Phase 1 Trial Of ST-001 NanoFenretinide In Relapsed/Refractory T- ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.